-
Mashup Score: 7Unanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in Chicago | Blood Cancers Today - 3 hour(s) ago
The panel mainly focused on how to define and classify myelodysplastic syndromes and clonal hematopoiesis of indeterminate potential.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 6The HemOnc Pulse Live | Blood Cancers Today - 17 hour(s) ago
Hosted by Chadi Nabhan, MD, the inaugural HemOnc Pulse Live will address unanswered questions in hematologic malignancies May 3-4 in Chicago.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
👏 We're only a few days away from #HOPLive24! 🎙️ Whether you're looking forward to the #bispecifics panel with @Rfonsi1, @mrbishop_UC_BMT, & @AaronGoodman33, or the #AML panel with @Daver_Leukemia & @MikkaelSekeres, there's lots in store! 🙌 Learn more: https://t.co/MydFt6GkqD https://t.co/3BeiSNz1vO
-
-
Mashup Score: 15Unanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in Chicago | Blood Cancers Today - 22 hour(s) ago
The panel mainly focused on how to define and classify myelodysplastic syndromes and clonal hematopoiesis of indeterminate potential.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5Dr. Osman on Autoimmunity, Female Sex, and KRAS Mutations in CMML | Blood Cancers Today - 1 day(s) ago
The case study included four patients with CMML who had KRAS mutations and a multitude of autoimmune diseases.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4Myelofibrosis | Blood Cancers Today - 2 day(s) ago
Myelofibrosis (MF) is a rare blood cancer that leads to scarring in the bone marrow, which alters the normal production of blood cells. Get the latest research and news.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2HMAs Are ‘Cornerstone’ in High-risk MDS Treatment Says Jamile Shammo, MD | Blood Cancers Today - 2 day(s) ago
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 10Meeting News | Blood Cancers Today - 3 day(s) ago
The online home of the latest conference coverage and meeting news for hematologic oncologists. View the latest news on Blood Cancers Today.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 3Liso-Cel ‘Favorable’ Safety Profile in Second-line Follicular Lymphoma | Blood Cancers Today - 3 day(s) ago
At a median follow-up of 18.1 months, the ORR and CR rates were both 95.7% following liso-cel treatment.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3
Drs. Lonial, Nabhan, and Stewart discussed the plenary session at ASH 2023, the PERSEUS trial, and treating smoldering MM.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 6The HemOnc Pulse Live | Blood Cancers Today - 4 day(s) ago
Hosted by Chadi Nabhan, MD, the inaugural HemOnc Pulse Live will address unanswered questions in hematologic malignancies May 3-4 in Chicago.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
👏 We're only a few days away from #HOPLive24! 🎙️ Whether you're looking forward to the #bispecifics panel with @Rfonsi1, @mrbishop_UC_BMT, & @AaronGoodman33, or the #AML panel with @Daver_Leukemia & @MikkaelSekeres, there's lots in store! 🙌 Learn more: https://t.co/MydFt6GkqD https://t.co/3BeiSNz1vO
-
Out now! 🥳 The #MDS panel from #HOPLive24 discusses: ☑️ How to classify and define MDS and CHIP ☑️ How to treat low- and high-risk MDS ☑️ How to approach transplant Check it out! https://t.co/TjZoRLTW2y @Ramikomrokji @Dr_AmerZeidan @drsangeetmd @sanamloghavi @chadinabhan https://t.co/YCj0AJ1oqq